The Precision Medicine Leaders Summit is proud to partner with one of the most prestigious and the oldest medical schools in the United States, The Perelman School of Medicine at the University of Pennsylvania. The UPenn School of Medicine provides the perfect backdrop to continue the discussion on the implementation of Precision Medicine, across not only large research institutions, but community settings where up to 85% of patients currently receive treatment.

Building on the successes of our events in San Diego and Jersey City, we hope you will join us for the most thought-provoking Precision Medicine event in the marketplace. Our speakers cover the panoply of leaders in the healthcare continuum, these include clinicians, industry experts, academics, regulators, payers, genetic counselors, bioinformaticians, and many more who are shaping the way Precision Medicine is implemented into healthcare systems on a global scale.

Join us for panel discussions, keynotes, roundtables, networking, exhibits, and opening reception to hear from thought leaders who are making the promise of Precision Medicine a reality.



Bristol-Myers Squibb


Thermo Fisher Scientific


Visual Strata
Genome Medical
Penn Medicine
University of Arizona
Regeneron Genetics Center


TUESDAY JUNE 11th, 2019


Registration & Breakfast Buffet


Welcome and Opening Remarks

David Roth, MD, PhD, Simon Flexner Professor and Chair of Pathology and Laboratory Medicine, Director, Penn Center for Precision Medicine, University of Pennsylvania Perelman School of Medicine

Nigel Russell, Founder & President, The Journal of Precision Medicine and the Precision Medicine Leaders Summits.


Pathology Imaging and Artificial Intelligence in Translational Medicine: From Exploratory Research to Commercialization

Michael Montalto, PhD, Vice President and Head of Translational Sciences at Bristol-Myers Squibb

Digital pathology, inclusive of the combination whole side imaging, advanced staining methods, image analysis and artificial intelligence, has the potential to transform our understanding of the pathophysiology of disease, improve diagnostic accuracy and reproducibility and harness workflow efficiencies in the clinical laboratory. This talk will explore various value propositions of digital pathology with emphasis on its role in exploratory clinical research for immune-oncology and, in this context, its potential as a platform for precision medicine.


Digital Pathology’s Impact on Precision Medicine Diagnostics

Moderator: George Lee, PhD, Digital Pathology Informatics Lead, Bristol Myers Squibb

Panelists: Michael Montalto, PhD,Vice President and Head of Translational Sciences at Bristol-Myers Squibb Anil Parwani, MD, PhD, MBA,Vice Chair and Director, Anatomic Pathology, Department of Pathology, The Ohio State University Wexner Medical Center Anthony Magliocco, MD, CEO, Protean BioDiagnostics, Inc, Michael Rivers , Vice President and Lifecycle Leader, Digital Pathology – Roche Tissue Diagnostics,

The field of pathology has always been central to diagnosis and precision medicine as crucial treatment decisions are routinely determined via interpretation of images under the microscope. The emergence of whole slide scanning and artificial intelligence technologies means that we have the potential to exponentially augment our capability around these images in terms of increased throughput, accuracy of diagnosis, and knowledge generation. This panel of key opinion leaders across medical centers and industry will share their insights and perspectives around current as well as future directions for digital pathology and what challenges remain towards its adoption for clinical use.


Advancing Precision Health with Approaches that Leverage Previously Unconnected Biomolecular and Clinical “Big Data”

Moderator: Yves A. Lussier, MD, FACMI, Associate Vice President for Health Sciences and Chief Knowledge Officer
Executive Director, Center for Biomedical Informatics and Biostatistics University of Arizona Health Sciences

Panelists: Jason H. Moore, PhD, FACMI, Edward Rose Professor of Informatics,Director, Institute for Biomedical Informatics,Director, Division of Informatics, Department of Biostatistics, Epidemiology, & Informatics,Senior Associate Dean for Informatics ,The Perelman School of Medicine University of Pennsylvania, Lara Mangravite, PhD, President, Sage Bionetworks, Michael Cantor, MD, MA, Executive Director, Clinical Informatics, Regeneron Genetics Center

The availability of Big Data across multiple dimensions, from electronic health records, lifestyles, environmental factors, genetics, to genomics, presents diverse challenges for existing informatics technology, in terms of computational efficiency, modeling effectiveness, statistical computing, discovery algorithms, and heterogeneous data integration. A growing trend is the creative integration of data collected independently for different purposes often not sharing common identifiers to enable novel analytical inferences unfeasible from smaller datasets. For example, novel toxidromes may be unveiled from jointly analyzing pollution data geospatially across different domains (i.e., air, land, and water) with clinical data. This panel will discuss analytics in the field of translational bioinformatics that strives to bridge the gap between disciplines among statistical genetics, clinical informatics, and bioinformatics as well as previously unconnected datasets (e.g., Emerge, GTEx, GEO, All of Us, UK Biobank, DrugBank), to advance precision health.


Coffee & Networking

11:00- 11:20am

Proteomics’ Coming-of-age in Personalized Health Management.

Steve Williams, MD, PhD, Chief Medical Officer, SomaLogic, Inc.

Proteins are important effector molecules, which mediate the impact of genes, the environment, co-morbidities, behaviors and drug treatments, but they have not been tested in studies of sufficient scale to examine whether their patterns could act as a sole information source for preventative health management. In the largest proteomics program performed to date, in 5 cohort studies with~17,000 participants, we measured ~5000 proteins in plasma samples using a modified aptamer (SOMAscan) assay, for a total of ~85 million individual measurements. We used machine-learning to derive protein patterns as predictors of clinical measures and validated them on data not used in derivation.
Protein-based models with good predictive performance were successfully validated for 6 measures of current health, 3 modifiable behaviors and 2 future risks. The first battery of these models is already being delivered to patients in a diabetes prevention setting, using the same platform. This approach could represent a scalable new paradigm for personalized health.


Pharmacogenomics – Precision Prescribing to Achieve Precision Medicine.

Moderator: Sony Tuteja, PharmD, MS,Research Assistant Professor of Medicine, Department of Medicine
Division of Translational Medicine and Human Genetics, Perelman School of Medicine at the University of Pennsylvania

Panelists: Kelly E. Caudle, Pharm.D., PhD., BCPS , Clinical Pharmacogenetics Implementation Consortium (CPIC) Director at St. Jude Children’s Research Hospital and is an affiliate Assistant Professor at The University of Tennessee Health Science Center, Philip Empey, PharmD, PhD, Associate Director of the Institute of Precision Medicine at the University of Pittsburgh and UPMC, Peter Silvester, Senior Vice President and President, Life Sciences Solutions, Thermo Fisher Scientific

Pharmacogenomics (PGx) promises improved medication outcomes if implementation challenges can be overcome. Over the last few years, the field has achieved a tipping point. With the broader availability of testing, publication of consensus guidelines for use of PGx data, and the dissemination of the successful strategies of early adopters, PGx implementations are becoming commonplace in a variety of settings. The panel brings together industry, academic, and healthcare institution thought leaders to share how they have accelerated pharmacogenomics adoption, what barriers remain, and what it would take to make a transformative leap forward towards ubiquitous preemptive testing at population scale.



1:00– 1:30pm

Update on All of Us Program

Stephanie Devaney, PhD, Deputy Director, All of Us Research Program, NIH

The All of Us Research Program is a key element of the Precision Medicine Initiative (PMI). Through advances in research, technology, and policies that empower patients, the PMI will enable a new era of medicine in which researchers, health care providers, and patients work together to develop individualized care.

PMI launched in fiscal year 2016 when $130 million was allocated to NIH to build a national, large-scale research participant group, called a cohort, and $70 million was allocated to the National Cancer Institute to lead efforts in cancer genomics as part of PMI for Oncology.

1:35 – 2:25pm

Precision Medicine Clinical Trials and Novel Designs: Levering Data, ‘Omics’, AI and Policy

Moderator: Arturo Loaiza-Bonilla, MD, MSEd, FACP, Vice Chair, Department of Medical Oncology, CTCA

Panelists: Julia A. Beaver, MD, Director of the Division of Oncology Products 1 (DOP1) Office of Hematology and Oncology Product, FDA, Gary Palmer, MD, Chief Medical Officer, Tempus, Inc Selin Kurnaz, PhD, CEO – Massive Bio

The paradigm changes from the ‘phenotype-to-genotype’ to the ‘genotype-to-phenotype’ approach has revolutionized R&D and Clinical trials in oncology and other diseases. This panel will discuss the impact of novel approaches to clinical trial design, including the use of technology, biomarker data and the current regulatory landscape which is moving the needle forward in earlier access and approval of promising compounds. The audience will be able to learn further about ‘basket’, ‘umbrella’, ‘seamless’, ‘adaptive’ design trials, synthetic control arms, ‘Just-In-Time (JIT) trials, as will have the opportunity to how different stakeholders are adapting to recent FDA policies and regulations for their R&D and clinical trial matching enrollment.


Biomarkers to Predict Response and Resistance to Targeted and Immunotherapies

Moderator: Nic Dracopoli, Consultant

Panelists: Timothy Chan MD, PaineWebber Chair in Cancer Genetics; Director, Immunogenomics and Precision Oncology Platform; Member, Human Oncology & Pathogenesis Program; Vice Chair, Department of Radiation Oncology; Director, Translational Oncology Division, Ilan “Lanny” Kirsch, M.D. Senior Vice President of Translational Medicine, Adaptive Biotechnologies

Dracopoli – Predicting response to targeted and immunotherapies

Kirsch – Immunosequencing in the service of immune-oncology

Chan – Genetic determinants of immunotherapy efficacy and resistance

This session will provide an update on the current use of biomarkers to predict response to targeted and immunotherapies in the treatment of cancer patients. Speakers in the session will discuss latest developments of deep sequencing of the T-Cell receptor to look for clonal T-cell infiltration in tumors as evidence of a prior suppressed immune response, evaluation of individual somatic alterations driving response to targeted signal transduction inhibitors, and to evaluate tumor mutation burden and HLA Class I antigen presentation to predict response to checkpoint inhibitors.


Coffee & Networking

3:45- 4:35pm

Innovation in Genomic Medicine Implementation

Moderator: Erica Ramos, MS, LCGC President National Society of Genetic Counselors and Director of Business development, Geisinger National Precision Health.

Panelists: Erynn Gordon, MS, LCGC, VP of Clinical Operations, Genome Medical, Tara Schmidlen, MS, CGC, Clinical Investigator/Genetic Counselor, Geisinger Health System, Leslie Bucheit MS, CGC, Product Manager, Digital Products, Myriad Genetics

While the technology and knowledge driving precision medicine continue to press ahead, how do we assure real value is realized for the acute setting equitably and at scale – and for populations, in context with fostering healthy communities. What are strategies to bridge the current landscape to a more harmonious future? What are we doing right? What will we regret? What will we laugh about? A panel of experts will have an honest assessment and share their vision for leaders in many facets of the field, from academia to industry to the community.

4:40 – 5:45pm

Improving Women’s Health Through Precision Care

Moderator: Amy Miller PhD, CEO – Society for Women’s Health Research

Panelists: Katie Johansen Taber, PhD, Senior Director, Clinical Development Myriad Women’s Health, Damian P. Alagia III, MD, MS, MBA, FACS, FACOG, Medical Director for Women’s Health and Reproductive Medicine for Quest Diagnostics, Susan McClure, CEO & Founder, Genome Creative, Jeffrey Shaman, PhD, Chief Science Officer, Coriell Life Sciences

Women have historically been underrepresented in health research, leading to care that may be suboptimal for their needs. This panel will discuss the current landscape of women’s health care, opportunities and challenges for drug and diagnostic development focused conditions specific to or more prevalent in women, optimizing the delivery of care for women, and the market opportunity for continued investment in research and development related to women’s health.


The Rise of Precision Patients

Grace Cordovano, PhD, CEO & Founder Enlightening Results, LLC

There is no denying it. We are in the midst of witnessing a historic shift in the culture of care: from paternalistic to participatory medicine. Patients are demanding not only the driver’s seat to their care, but also stepping on the accelerator, ready to drive through whatever barriers stand in the way of getting the care they need.

Join me as I amplify the patient perspective on:
-what patients’ value, prefer, and need
-the critical roles of shared decision making, empathy, and digital technology for improving the patient experience and delivery of care at N of 1.
-the importance of partnering with patients to advance human data science, improving clinical trial design & recruitment, & transforming the culture of research and care.
-the need to include patients at conferences, both in attendance & speaking to disseminate credible content & infuse patient perspectives to truly deliver value.
-leveraging social media to improve health literacy, patient education, peer to peer health support, and access to precision medicine.


Networking Reception at Penn Museum (China & Egypt Exhibits) – enjoy drinks and hors d’houvres with fellow attendees, speakers and sponsors.



Breakfast Buffet


Advancing Personalized Medicine Through Shared Value

Edward Abrahams, Ph.D. President, Personalized Medicine Coalition


Keynote: Expanding Precision Medicine

Reto Merges, Global Head of Expanding Precision Medicine, Siemens Healthineers


Gene Editing – The Breakthrough Technology

Moderator: Eric Kmiec, PhD, Director, Gene Editing Institute, Center for Translational Cancer Research, Helen F. Graham Cancer Center and Research Institute, Christiana Care Health System

Panelists: Lorenz Mayr, PhD, Chief Technology Officer, GE Healthcare, Ben Zeskind, PhD, MBA, Co-Founder and CEO, Immuneering Corporation, Giorgio Sirugo, MD, PhD, Adjunct Associate Professor of Medicine, Perelman School of Medicine, University of Pennsylvania

CRISPR-directed human gene editing, is a form of precision medicine that is considered to be a breakthrough technology. While certainly not alone in this space, transition from bench to bedside requires that these technologies, especially for therapeutic use, are not only reproducible but robust. This line of thinking means that outstanding technological advances made in top laboratories around the world with unlimited resources are viewed as exciting and dramatic science. But, unless these technologies can be carried out within a diverse patient population, they will have little impact on patient care and will not be delivered in an efficient fashion. A robust technology means that just about every location or caregiver can carry out the process and isn’t limited to specific sites around the country that have the highest degree of technological and service expertise.

9:45 – 10:05am

Immune Health

Robert Vonderheide, MD, DPhil, Director of the Abramson Cancer Center, John H. Glick Abramson Cancer Center Professor, Perelman School of Medicine, University of Pennsylvania

Immunology is now central to the treatment of many human diseases and immune-based drugs are transforming clinical care. It is now possible to perform sophisticated high dimensional profiling of human immune system diversity or function. Capitalizing on these advancements, we propose a new dimension of medicine called Immune Health. This approach captures science in humans occurring regularly in the clinic, applies sophisticated immune profiling and integrated data analysis, and translates these data into quantitative, actionable immune health information and deliver back to the clinic.

10:05 – 10:35am

Coffee & Networking


Mind the Gap: Are Mutational Profiles Sufficient for Precision Medicine?

Moderator: John Quakenbush, PhD, Henry Pickering Walcott Professor of Computational Biology and Bioinformatics
Chair, Department of Biostatistics, TH Chan School of Public Health, Harvard

Panelists: Benjamin Haibe-Kains, PhD, Senior Scientist, Princess Margaret Cancer Centre (PM), University Health Network, and Associate Professor in the Medical Biophysics Department of the University of Toronto, Christos Hatzis, PhD, Adjunct Associate Professor of Medicine, Section of Medical Oncology, Yale School of Medicine, Yale University, Clinical Mechanisms Lead, Translational Medicine, Bristol-Myers Squibb

Much of precision medicine has been built on the idea that we can match patients to appropriate therapies based on their genetic background or that of their disease. But despite the success of targeted therapies and their associated biomarkers, not every patient with or without the “predictive” mutation responds as expected to the associated therapy. This suggests that single biomarkers are not sufficient and argues for more sophisticated, network medicine approaches. This panel will explore the limits of current precision medicine strategies and the ways in which these might be extended to better match patients to the most appropriate therapy.


Expanding Precision Medicine by Improving Diagnostic Accuracy

Moderator: Luis M. Lasalvia, MD, VP & Global Medical Officer, Siemens Healthineers

Panelists: Kenneth J. Pienta, MD. The Donald S. Coffey Professor of Urology, Professor of Oncology, Professor of Pharmacology and Molecular Sciences, The Johns Hopkins Hospital. Dwight Raum, Vice President & Chief Technology Officer, The Johns Hopkins University and the Johns Hopkins Health System

The goal of expanding precision medicine is to deliver precision medicine to every patient. Medicine today is generally based on a “one-size-fits-all” practice, and where targeted therapies are possible, it is impractical to scale. Based on data integrated from multiple sources, a precise understanding of a patient’s condition is the most effective approach to deliver outcomes favorable to all stakeholders. This includes the discussion of the value and role of data analytics and decision support systems for managing information. Aiming to deliver precision medicine at the right place, the panelists will share and discuss with the audience on how leaders can start precision medicine initiatives, as well as suggested paths executives can take for scaling up within an organization.



1:15 –1:45pm

Fireside Chat: Population Health and Precision Medicine Working in Harmony

David B Nash, MD, MBA, Dean Jefferson College of Population Health, Dr. Raymond C. & Doris N. Grandon Professor of Health Policy, Thomas Jefferson University

David Roth, MD, PhD, Simon Flexner Professor and Chair of Pathology and Laboratory Medicine, Director, Penn Center for Precision Medicine, University of Pennsylvania Perelman School of Medicine


Diagnostic and Clinical Data Integration: A Framework for Improving Quality of Care

Moderator: Lori Anderson, Product Marketing Manager, XIFIN, Inc

Panelists: Wendy Rubinstein, MD, PhD, Deputy Medical Director, CancerLinQ, LLC, American Society of Clinical Oncology, Shawn Glisson, MD, Medical Oncology / Hematology, Norton Cancer Institute, Omar Perez, PhD, RAC, Head of Precision Medicine and Diagnostics R&D, GSK

Despite the advances in health care data interoperability, multimodal patient data remains trapped in disparate data systems creating access problems for clinicians and complicating information sharing between multidisciplinary teams. The promise of precision medicine is to improve the quality of patient care by leveraging diagnostic data to drive clinical treatment decisions that result in better patient outcomes. Breaking down data silos allows organizations to design, track and document new quality metrics for the purpose of continuously improving quality of care for clinicians as well as enabling the development of clinical evidence necessary to establish medical necessity, actionability and clinical utility for diagnostics.


Precision Oncology – How The “End of Average” Transforms Clinical Decision Making

Okan Ekinci, MD, MBA, Chief Medical Officer – Roche Diagnostics Information Solutions


The Growing Role of Molecular Tumor Boards in Precision Oncology

Moderator: Kimberley Ferguson, Market Development Executive, Roche Diagnostics Information Solutions

Panelists: Daniel Anaya, MD, FACS – Chief of GI Surgery and Head of Hepatobiliary Section in the Department of Gastrointestinal Oncology, Moffitt Cancer Center Cancer Center, Jennifer Johnson, MD, PhD, FACP Assistant Professor in Medical Oncology, Thomas Jefferson University, Christian Squillante, MD, Department of Hematology and Medical Oncology, Cooper University Health Care

While the purpose of molecular tumor boards in precision oncology continues to evolve, cancer providers now practice in an era where vast amounts of biomolecular, phenotypic and genotypic information have become pivotal to the decisions made about patient care. Rapid technical advances, steeply declining sequencing costs, and the ever-increasing number of targeted therapies, mean that extensive tumor sequencing such as whole-exome and whole-genome sequencing will soon be applied as the standard of care. There is also a rapidly growing gap between clinical knowledge and genetic potential in cancer care. Now is a prime time for cancer programs to assess how these tumor boards may enhance care and provide additional support and resources for their providers and patients. Molecular tumor boards can serve several key purposes, including: clinical research, continuing education, collaboration and engagement. As the term “precision medicine” becomes more ubiquitous in cancer care delivery, the role of molecular testing is increasingly an integral part of shaping personalized treatment decisions and care plans. Cancer therapy that is driven by genomic testing can lead to more personalized treatment approaches that improve clinical outcomes.


Coffee & Networking


Genetic Susceptibility to Breast and Ovarian Cancer: Risk Prediction to Therapy

Susan M. Domchek, MD is the Basser Professor in Oncology at the Perelman School of Medicine of the University of Pennsylvania, Executive Director of the Basser Center for BRCA at the Abramson Cancer Center and Director of the Mariann and Robert MacDonald Cancer Risk Evaluation Center


Implementation of a State-Wide Community Genomics Initiative in Maine

Andrey Antov, PhD, MBA  Founding Program Director of The Maine Cancer Genomics Initiative, The Jackson Laboratory

The Maine Cancer Genomics Initiative (MCGI) is the first-of-its-kind community-based genomic medicine program in Maine. Its goal is to deliver the very best precision cancer treatment across the entire state and further connect regional care centers with urban clinical trials for the best patient outcomes. The Initiative is covering the cost of genomic sequencing for 1,800 patients. MCGI is filling the gap between innovation and implementation, providing education to clinicians and patients and, most importantly, making genomic testing accessible so that it can be adopted as a regular practice for Maine patients with cancers of varying complexity.


Closing Remarks


Steve Williams

Stephen A Williams MD PhD

Chief Medical Officer, Somalogic Inc.

Steve is currently Chief Medical Officer, SomaLogic Inc. in Boulder CO. Our mission is to scan the living data stream of human proteins with great precision, sensitivity and scale and translate it into actionable insights for every seeker and enabler of human health. This mission capitalizes on the proprietary SOMAscan 5000-plex protein assay.
Since joining SomaLogic in 2009, Steve has been responsible for the Clinical R&D that enables discovery and qualification of machine-learning derived protein patterns – “health insights”, derived from blood samples that mimic the best objective measures of current and future state of health. Additionally, Steve is responsible for studies that prospectively measure products’ impact and utility.
Steve has been involved in a number of notable biomarker initiatives throughout his career from authorship of PhRMA position papers on “proof of concept”, surrogate endpoints and evidentiary standards for biomarkers and diagnostics, through helping to initiate the biomarkers consortium and the Alzheimer’s Disease NeuroImaging (ADNI) study, teaching drug and regulatory science at UCSF, and continues today with involvement in the FNIH-FDA-Industry working group on biomarker evidentiary standards.
From 2003-2007 Steve was on the National Advisory Council for Biomedical imaging and Bioengineering at the National Institutes of Health and chaired the committee on Training and Development.
From 1989-2007 Steve was at Pfizer Inc., in the UK and in the US; initial work was in Experimental Medicine, performing Exploratory Clinical Development studies (including successes such as eletriptan, sertraline, ziprasidone, darifenacin and varenicline, as well as numerous failures!) and subsequently as VP, Worldwide Head, Clinical Technology, responsible for qualifying and implementing innovative technologies to improve the productivity of drug development. In 2007 he authored the self-help book “Decisionability”.
Steve has an honours degree in physiology, UK medical degrees, and a PhD in medicine and physiology (mentored by Sir John Tooke), all from Charing Cross and Westminster Medical School, (now in Imperial College London); he also obtained training in diagnostic imaging at the University of Newcastle Upon Tyne.

Susan Domchek

Susan M. Domchek, MD

Basser Professor in Oncology at the Perelman School of Medicine of the University of Pennsylvania. Executive Director of the Basser Center for BRCA at the Abramson Cancer Center and Director of the Mariann and Robert MacDonald Cancer Risk Evaluation Center

Susan M. Domchek, MD is the Basser Professor in Oncology at the Perelman School of Medicine of the University of Pennsylvania. She serves as Executive Director of the Basser Center for BRCA at the Abramson Cancer Center and Director of the Mariann and Robert MacDonald Cancer Risk Evaluation Center. Her work focuses on the genetic evaluation and medical management of individuals with inherited risk factors for cancer. Dr. Domchek is particularly interested in developing new cancer therapies, such as PARP inhibitors, for breast cancer patients due to genetic risk factors. An elected member of the National Academy of Medicine, American Association of Physicians, and American Society of Clinical Investigation, Dr. Domchek is also a member of the American Society of Clinical Oncology for which she had served on a number of committees. A significant contributor to the oncology literature, she has authored/co-authored more than 250 articles appearing in scholarly journals including the New England Journal of Medicine, the Journal of the American Medical Association and the Journal of Clinical Oncology. Dr. Domchek also serves on a number of editorial review boards, as well as on the Scientific Advisory Board for the Breast Cancer Research Foundation.

Susan Domchek

Giorgio Sirugo, MD, PhD

Co-Director Center Penn Medicine Biobank and adjunct Associate Professor of Medicine at the University of Pennsylvania, Perelman School of Medicine.

Giorgio Sirugo, MD, PhD, is a medical geneticist, whose primary research focus is on the genetic susceptibility to infectious diseases. Dr. Sirugo has extensive expertise in this area of studies, having been, prior to the current appointment, Head of the Human Genetics laboratory and Research Clinician at the MRC Unit in The Gambia (West Africa). While in The Gambia he created and directed the first DNA bank in sub-Saharan Africa, funded by the MRC UK in the year 2000. He participated, as a co-investigator, in the Wellcome–Trust Consortium for genome-wide association studies of tuberculosis and malaria. He is currently scientific co-director of the Penn Medicine Biobank and adjunct Associate Professor of Medicine at the University of Pennsylvania, Perelman School of Medicine.

Mike Montalto

Michael Montalto, PhD

Vice President and Head of Translational Sciences at Bristol-Myers Squibb

Dr. Montalto is currently the Vice President and Head of Translational Sciences at Bristol-Myers Squibb (BMS). In this role, he oversees the majority of clinical biomarker platforms in Translational Medicine including translational and digital pathology, clinical genomics, clinical flow cytometry, pre-clinical and clinical imaging, biorepository and clinical biomarker sample operations in support all therapeutic areas for global clinical trials, precision medicine and companion diagnostics development. Prior to BMS, Dr. Montalto was a co-founder and executive of Omnyx, LLC, a joint venture of GE Healthcare and the University of Pittsburgh Medical Center that commercialized diagnostic pathology imaging and software products. Omnyx was sold by GE Healthcare to Inspirata in 2017. Prior to this, Dr. Montalto was the Molecular Imaging and Diagnostics Advanced Technology Leader at GE Global Research Center, where he led the discovery efforts of non-invasive imaging technologies and was a lead inventor of MultiOmyx™ , a proprietary pathology-based multiplexing technology for biomarker discovery currently sold through Neogenomics, Inc. He has served as a member of NIH study sections for in vivo molecular imaging centers, designed and led global clinical trials for the registration of digital pathology devices and served as chair of the regulatory task-force of the Digital Pathology Association (DPA). Under his leadership, the DPA successfully collaborated with the FDA to establish industry wide regulatory guidances and clinical designs for the clinical use of digital pathology devices. He currently serves on the board of directors as the Past-President of the DPA. Dr. Montalto earned his PhD in tumor biology from Albany Medical College and received his post-doctoral training in anti-inflammatory drug discovery and whole animal physiology at Brigham and Women’s Hospital, Harvard Medical School.

Michael Rivers

Michael Rivers

Vice President and Lifecycle Leader, Digital Pathology – Roche Tissue Diagnostics

Michael joined Roche Tissue Diagnostics in 2006 and has been Lifecycle Leader for Digital Pathology since October 2015. In this role he leads the Digital Pathology team in Santa Clara, California to develop and commercialize the Digital Pathology portfolio of products and technology for Roche.
Prior to this Michael was the general manager of the research business at Roche Tissue Diagnostics. In this position he was responsible for the management of Roche’s Discovery product line, as well as leadership of Spring Bioscience, Roche’s wholly owned subsidiary specializing in the development and production of rabbit monoclonal antibodies designed for IHC applications. Michael has held a number of sales and marketing leadership roles at Roche Tissue Diagnostics and is passionate about the opportunity to impact cancer diagnostics with Digital Pathology.

Grace Cordovano

Grace Cordovano, PhD.

CEO & Founder , Enlightening Results, LLC

`Upon recognizing significant unmet needs and challenges in patients’ experiences throughout their cancer diagnosis, Dr. Grace Cordovano founded Enlightening Results in 2010. As the culmination of her life’s experiential learning and education, Dr. Cordovano is dedicated to fostering personalized patient advocacy services, specializing in the oncology space. She strategically guides her clients through survivorship or end-of-life care planning with empathy, ensuring they are armed with the most pertinent, medically credible, easy to understand information and tools to make empowered decisions about their care. Through her advocacy work, she is humbled to witness first-hand the challenges, the barriers to access, the unmet needs, the grief, the joys, the suffering, the financial toxicities, and the losses patients face in the midst of a diagnosis. She has made these insights actionable as a patient experience enhancer.
Dr. Cordovano is a firm believer in the continuous advancement of patient education, engagement, empowerment, and experiences through the infusion of empathy, design thinking, technology, and compassionate business strategy. As a patient opinion leader, she elevates the patient and carepartner’s voice in discussions on maximizing accessible innovation, digital transformation, enhancing diversity, improving patient outcomes, and the culture of value based, human-centered care. Dr. Cordovano is passionate about leveraging digital tools and social media to deliver content that resonates with patients, that is crafted in a culturally sensitive manner and at an appropriate health literacy to deliver authentic value.
Dr. Cordovano completed her Masters and Ph.D. in Biochemistry at Albert Einstein College of Medicine, Bronx, NY. She is a board-certified patient advocate via the international credentialing of the Patient Advocate Certification Board. She is a proud member of the Alliance of Professional Health Advocates, Society of Participatory Medicine, Savvy Cooperative, and Health 2.0 NYC. She serves as an e-patient ambassador for the Coalition of Compassionate Care of California and is a contributor for Tincture. Dr. Cordovano has been repeatedly recognized as Patient Advocate of the Year, most recently at the 2019 Health IT and Marketing & PR Community Conference Medigy Awards.
Follow her on Twitter at @GraceCordovano.

Jeff Shaman

Jeffrey Shaman, PhD.MS

Chief Scientific Officer, Coriell Life Sciences

Dr. Jeffrey Shaman is the Chief Science Officer at Coriell Life Sciences where his expertise in genetics, pharmacology, stem cells, and clinical laboratory operations is used to develop and promote genetic and medication risk reporting tools for healthcare professionals and patients.
Dr. Shaman earned his MS from The University of Medicine and Dentistry of New Jersey in Cell & Developmental Biology, and a PhD from The Johns Hopkins University School of Medicine in Pharmacology & Molecular Sciences, where his research focused on DNA, epigenetics, and nuclear structure and function. Subsequently, he held a faculty position at the University of Hawai‘i Institute of Biogenesis Research before moving to Harvard Medical School, Beth Israel Deaconess Medical Center, and the Bedford Stem Cell Research Foundation, where he bridged the gap between research and medicine thru genetic and clinical medicine initiatives. Dr. Shaman was recruited to Coriell Life Sciences from an international DNA sequencing provider, where he established Translational Genomics activities as a revenue-rich market vertical providing regulatory (FDA) and clinical (CLIA/CAP) services to international pharmaceutical companies, healthcare providers, physicians, and patients. He continues to lecture and publish on topics including pharmacogenomics, bioethics, and clinical care.

Reto Merges

Reto Merges

Global Head of Expanding Precision Medicine Siemens Healthineers

With more than 15 years’ leadership experience in healthcare, Reto Merges has a strong track record in building effective teams for clinical innovation and marketing. He has four years of work experience in China, ramping up efforts for research collaboration in China and Korea. He holds an engineering degree in electrical engineering and information technology from the Karlsruhe Instituteof Technology, Germany, and has studied at the Nanjing Normal University, China. His scientific background is in the field of medical imaging where he has authored many publications, while submitting multiple patents.

Kimberley Ferguson

Kimberley Ferguson

Market Development Executive, Roche Diagnostics Information Systems

Kimberley Ferguson is a Market Development Executive with Roche Diagnostics Information Solutions. In this role, Kimberley is identifying and maturing bioinformatics driven opportunities in focused healthcare settings, including; academic medical centers, oncology clinical decision support and tumor boards. Kimberley is a tenured marketing and sales professional as well as a scientist, and holds dual Bachelor of Science degrees in Microbiology and Biochemistry from San Diego State University and holds additional certifications in innovation and bioinformatics from Stanford University.
Kimberley has spent the past three years focusing on both the coalescence of large clinical data sets in disparate healthcare settings, and the utilization of “omics,” to facilitate data driven discovery from bench to bed-side. She spent a year and a half as the Executive Vice President of Sales and Marketing at Signet Accel, a technology start-up in Columbus, Ohio – that focused on an interoperability platform in the healthcare IT arena. Kimberley also spent a year and half working for Illumina and during this time she was focused on the tumor board setting and clinical decision support tools that enhanced discussions focused on the “genomics” aspect of cancer treatment. Kimberley has more than twenty years of sales experience in healthcare including ten and half years at Roche Diagnostics.

Kimberley’s varied background in sales, healthcare, informatics, marketing and hospital diagnostics have provided the perfect foundation for developing the market and selling informatics solutions in oncology settings in Roche’s newest business endeavor – to digitize healthcare.
To contact Kimberley please email Kimberley.ferguson@roche.com and learn more at LinkedIn.

Gary Palmer

Gary Palmer, MD, JD, MBA, MPH

Chief Medical Officer, Tempus Labs, Inc.

Dr. Gary Palmer serves as Chief Medical Officer at Tempus, where he is responsible for leading clinical activities for the company and supporting external collaborations and strategic partnerships. Dr. Palmer most recently served as the Chief Medical Officer for NantHealth. Prior to his time there he served as Senior Vice President, Medical Affairs and Commercial Development at Foundation Medicine, where he helped launch the FoundationOne assay. Earlier in his career, Dr. Palmer served as the Chief of Medical Oncology at Mercy Health System, Sacramento and head of their Oncology Service Line. Prior to that he was as an Associate Professor of Medicine at University of California Davis Cancer Center. He earned a bachelor’s degree from Yale University, his medical degree from Stanford University School of Medicine and his masters of public health from the UCLA Fielding School of Public Health.

Dwight Raum

Dwight Raum

Vice President and Chief Technology Officer of Johns Hopkins Health System and Johns Hopkins University

Dwight Raum is Vice President and Chief Technology Officer of Johns Hopkins Health System and Johns Hopkins University. With Johns Hopkins over 17 years, Dwight serves as a leader in IT infrastructure operations, product innovation, university information systems and precision medicine. His passion lies in challenging the status quo, mobilizing teams to harness technology and championing change.

Dwight’s responsibilities envelop several levels of technology, but start with core, foundational IT infrastructure. This includes services such as data center, storage, compute, helpdesk and cybersecurity. Proficient infrastructure affords Hopkins opportunity and capacity to explore new ways of generating value from its technology investments. Dwight’s leadership has been instrumental transforming how Hopkins uses technology to meet its mission.

In 2014, Dwight cofounded the Technology Innovation Center (TIC) and now serves as its Executive Director. The TIC cultivates innovative faculty and teams them with technical experts to solve problems. Since its inception, TIC led initiatives have demonstrated improved patient care by bettering access to information, optimizing workflows, applying novel technologies and improving communications. The TIC also partners with early stage startups. As a liaison, the TIC helps to navigate and balance disruptive change with the rigors of a complex medical enterprise. Recognizing change occurs at the speed-of-trust, the TIC also fosters several leadership development programs and convenes events to connect informal change agents.

Dwight also leads technical platform implementation of the Johns Hopkins precision medicine initiative called inHealth. InHealth combines research, data science, technology and clinical disciplines into an integrated program that is transforming the standard of care into precision medicine. The technical core of this platform is a cloud-based big-data system, upon which multiple diseases are simultaneously investigated using genomics, computer vision, machine learning and deep neural networks. The initiative seeks to improve individual and population health outcomes by accelerating the pace of discovery and ensuring innovations transition to care delivery. Dwight helped crystalize the strategy around the platform’s architecture and critical components, and assembled a technical team capable of rapid execution. This work is modernizing research tools, while improving access to data. InHealth is ushering in a new era of discovery, treatment, and outcomes for patients.

As part of his role as Chief Technology Officer, Dwight has improved the proficiency of delivery from the IT organization and aligned technology with Johns Hopkins missions. He promotes the transformational power of a service-oriented organization that maintains consolidated and integrated IT systems. Dwight’s vision is based on ensuring market competitiveness, committing to value, and promoting service excellence.

Ben Zeiskind

Ben Zeskind, PhD, MBA

Co-Founder and CEO, Immuneering

Dr. Zeskind co-founded Immuneering in 2008 with the goal of leveraging high-throughput data to improve pharma R&D. He is an inventor on numerous patents assigned to both Immuneering’s partners and the company itself, and has published extensively in peer-reviewed journals. He trained at MIT, earning a Ph.D. in Bioengineering in 2006 and an S.B. in Electrical Engineering and Computer Science in 2003. He also earned an MBA at Harvard Business School in 2008, where he was recognized as a Baker Scholar, the highest award for distinction.

Pat Alagia

Damian P. Alagia III, MD, MS, MBA, FACS, FACOG

Franchise Medical Director for Women’s Health and Reproductive Medicine for Quest Diagnostics

Dr. Alagia is an experienced clinician, academician, and health care executive. As the founding partner of a large obstetrics, gynecologic, and surgery practice he understands firsthand the need to adapt and innovate in an ever changing healthcare environment. His commitment to patient care and innovation led him to become a subject matter expert in medical devices for Johnson and Johnson where he created a minimally invasive gynecologic surgical program which he later deployed at The George Washington University Hospital. From this platform Dr. Alagia applied his skills to a Silicon Valley venture capital backed startup company where he and the other members of the turnaround team, realigned the development strategy leading to the successful sale of the company. Following the sale he became the Chief Physician Executive of the newly formed $2.5B KyOne Health system where he had responsibility for the strategic alignment of the academic and community physicians, clinical integration, quality, safety, service line formation, and clinical research, as well as serving as Chairman of an award winning 120,000 member ACO. In his current position as the Franchise Medical Director for Women’s Health and Reproductive Medicine for Quest Diagnostics he has portfolio responsibility and oversite of core product offerings, new product development, clinical research design and implementation, health system alignment, and franchise growth.

Dr. Alagia is a board certified obstetrician and gynecologist who is both a fellow of the American College of Surgeons and the American College of Obstetrics and Gynecology, He is a graduate of Georgetown University College and Medical School and holds Masters Degrees in Business and Finance from The Johns Hopkins University.

Christos Hatzis

Christos Hatzis, PhD.

Adjunct Associate Professor of Medicine, Section of Medical Oncology, Yale School of Medicine, Yale University, Clinical Mechanisms Lead, Translational Medicine, Bristol-Myers Squibb

Susan McClure brings over 31 years of journalistic experience to her role as CEO and founder of Genome Creative. Prior to that she was publisher and founder of Genome magazine— the first consumer magazine exclusively devoted to covering the world of personalized medicine and the genomic revolution that makes it possible. Prior to its launch, she spent 10 years as the publisher of CURE — a magazine for cancer patients, survivors, and caregivers. During her tenure at CURE, she also served as vice president of patient engagement for McKesson Specialty Health.In 2016, Susan was honored by Folio as one of the “Top Women in Media” and was invited by the Personalized Medicine Coalition to its board of directors — the first journalist to receive such an honor. She has over 23 years of experience delivering first-class sales and management strategies to leading and start-up media and healthcare organizations.

Tony Magliocco

Susan McClure

CEO & Founder, Genome Creative

Susan McClure brings over 31 years of journalistic experience to her role as CEO and founder of Genome Creative. Prior to that she was publisher and founder of Genome magazine— the first consumer magazine exclusively devoted to covering the world of personalized medicine and the genomic revolution that makes it possible. Prior to its launch, she spent 10 years as the publisher of CURE — a magazine for cancer patients, survivors, and caregivers. During her tenure at CURE, she also served as vice president of patient engagement for McKesson Specialty Health.In 2016, Susan was honored by Folio as one of the “Top Women in Media” and was invited by the Personalized Medicine Coalition to its board of directors — the first journalist to receive such an honor. She has over 23 years of experience delivering first-class sales and management strategies to leading and start-up media and healthcare organizations.

Tony Magliocco

Anthony Magliocco, MD

Chair of Anatomic Pathology at the Moffitt Cancer Center and Executive Director of Esoteric Laboratory Services & CEO and President Protean Biodiagnostics

Dr Magliocco has over 25 years experience as a Professor, Researcher, Pathologist, Laboratory Director, Consultant, Tissue Banker, and public speaker. He is Board Certified in Anatomic Pathology and has extensive experience and sub-specialty expertise in Breast, Gyn, and Molecular Pathology. He has held continuous peer reviewed funding in translational research and his laboratory is currently investigating the mechanisms of ovarian cancer metastasis and treatment evasion.
He has founded numerous molecular diagnostic laboratories in the USA and Canada, has published over 200 manuscripts in oncology, and holds numerous diagnostic technology patents.
He is currently Chair of Anatomic Pathology at the Moffitt Cancer Center and Executive DIrector of Esoteric Laboratory Services. In 2017 he founded a new biotechnology company Protean Biodiagnostics and currently acts as CEO and President.
He has held numerous national and international roles including Chair of Pathology for the Radiation Therapy and Oncology Clinical Trials group, member of the NCI GU steering committee, and member of the Canadian Cancer Clinical Trials Network Steering committee, as well as previous editorial position with the Journal of Surgical Oncology and is frequent reviewer for numerous other Oncology and Pathology Journals.

Sony Tuteja

Sony Tuteja, PharmD, MS

Research Assistant Professor in the Department of Medicine at the Perelman School of Medicine at the University of Pennsylvania.

Dr. Sony Tuteja, PharmD, MS, is a clinician-scientist focused on understanding the mechanisms contributing to variability in response to drug therapy or pharmacogenomics. Her translational research includes application of genomics, metabolomics and metagenomics to discover novel markers of response to lipid lowering therapies. Her clinical interests include implementation of pharmacogenomics into clinical practice. She is a Research Assistant Professor in the Department of Medicine at the Perelman School of Medicine at the University of Pennsylvania.

George Lee

George Lee, PhD.

Digital Pathology Informatics Lead, Bristol Myers Squibb

George Lee received his PhD in Biomedical Engineering at Rutgers University and has over 10 years of expertise in the areas of digital pathology, machine learning, and clinical oncology. He has authored over 30 peer-reviewed manuscripts and abstracts and holds several patents for image-based companion diagnostics. Currently, at Bristol-Myers Squibb, he is partnering with image analysis vendors to develop and validate pathology image-based pipelines to provide mechanistic and clinically relevant insights of immunotherapy response. Previous to working at BMS, he served as a Research Assistant Professor in the Biomedical Engineering Department at Case Western Reserve University developing machine learning and image-analysis methodologies for modeling the progression of prostate cancer.

Kelly Caudle

Kelly E. Caudle, Pharm.D., Ph.D., BCPS

Clinical Pharmacogenetics Implementation Consortium (CPIC) Director at St. Jude Children’s Research Hospital & affiliate Assistant Professor at The University of Tennessee Health Science Center

Kelly E. Caudle, Pharm.D., Ph.D., BCPS is the Clinical Pharmacogenetics Implementation Consortium (CPIC) Director at St. Jude Children’s Research Hospital and is an affiliate Assistant Professor at The University of Tennessee Health Science Center. Dr. Caudle oversees the CPIC guideline development process including the coordination of the guideline writing committees, the guideline evidence reviews, and the writing of the guideline manuscript and supplement as well as coordinates all CPIC-related activities and projects. She also serves as a preceptor for a pharmacogenetics APPE rotation and is involved in the clinical implementation of pharmacogenetics at St. Jude Children’s Research Hospital. She has several publications in the area of pharmacogenetics and implementation of pharmacogenetics into clinic.

Anil Parwani

Anil Parwani, MD, PhD.

Vice Chair and Director, Anatomic Pathology, Department of Pathology, The Ohio State University Wexner Medical Center

Anil Parwani is a Professor of Pathology and Biomedical Informatics at The Ohio State University. He also serves as the Vice Chair of Anatomical Pathology and Director of Division of Pathology Informatics and Digital Pathology. Dr. Parwani is a world leader in digital pathology and has led the way in the implementation of these technologies in several key clinical areas. He also has expertise in the area of Anatomical Pathology Informatics including designing quality assurance tools, biobanking informatics, clinical and research data integration, applications of whole slide imaging, digital imaging, telepathology, image analysis, artificial intelligence and lab automation. Dr. Parwani has authored over 300 peer-reviewed articles in major scientific journals and several books and book chapters.

Lori Anderson

Lori Anderson

Product Marketing Manager, XIFIN, Inc.

Lori Anderson is product marketing manager for precision medicine informatics at XIFIN, where she brings many years of experience in medical affairs and product portfolio management in the healthcare and life-sciences industries. Prior to joining XIFIN, Lori was the director of health economics and outcomes research at Quest Diagnostics where she defined the reimbursement strategy for numerous tests routinely used in precision medicine. As a laboratorian herself with a particular interest in hematological neoplasms and the role of platelets in cardiovascular disease, Lori has contributed to the publication of 10 book chapters, 20 peer reviewed publications and over 40 poster presentations and has presented on numerous topics in laboratory medicine and life sciences worldwide.


Shawn Glisson, MD

Medical Oncology/Hematology, Norton Cancer Institute

Dr. Shawn Glisson MD, board certified in Medical Oncology and Hematology received his M.D. from the University of Louisville Kentucky. He completed his clinical fellowship in Oncology/Hematology at the University of Louisville Hospitals and Clinics, Louisville, KY and a research fellowship in Molecular Biology and Clinical Oncology from the University of Colorado School of Medicine, Given Biomedical Institute, Aspen, CO. Dr. Glisson served in the military retiring honorable as a Colonel in 2009. He has held numerous chair, director and teaching positions in several health care and professional organizations. He has presented at numerous nationals and international meetings and co-authored numerous peer reviewed publications, book chapters and governments reported throughout his esteemed career. Dr. Glisson currently sees patients at the Norton Cancer Institute at the Pavilion, Norton Healthcare in Louisville, KY and also at the King’s Daughter’s Health’s Cancer Center in Madison, IN.


Okan Ekinci, MD, MBA

Chief Medical Officer, Roche Diagnostics Information Solutions

Okan Ekinci is the Chief Medical Officer for Diagnostics Information Solutions (DIS) at F. Hoffmann La-Roche Ltd in Basel, Switzerland. He is a member of the leadership team of DIS, an organisation focused on decision support solutions, powered by aggregated data and advanced analytics, in support of Roche’s personalised healthcare (PHC) strategy. The goal is to redefine how data and analytics can drive patient care and R&D to help ensure the right treatment reaches the right patient.

Okan has 20+ years of experience in the healthcare sector, including 8 years of clinical practice in cardiology. Before joining Roche, he was Global Head & Vice President of the Healthcare Consulting business at Siemens Healthineers, developing and offering IT-enabled transformation and clinical consulting services. With his team he introduced data-driven innovative offerings such as Radiology Performance Management Services and 4D Workflow Simulation Services for healthcare institutions. Prior to that, he established the Global Medical Office of Healthineers and served as its first CMO, across imaging, in-vitro diagnostics and healthcare IT.

Okan is an adjunct Professor of Medicine at University College Dublin, Ireland, holds an MBA from the European School of Management and Technology, Berlin and an MD from University of Mainz, Germany. He’s an alumni of Harvard Business School‘s Value-based Healthcare program.

Laura Beaver

Julia A. Beaver, MD

Director, Division of Oncology Products 1 (DOP1), Office of Hematology and Oncology Products, FDA

Julia A. Beaver, MD, is the Director of the Division of Oncology Products 1 (DOP1) in the Office of Hematology and Oncology Products at the U.S. Food and Drug Administration (FDA). She is also an Assistant Professor of Oncology, part-time, at Johns Hopkins University where she is a member of the Johns Hopkins Breast Cancer Group. Dr. Beaver serves on the Liquid Biopsy Blood Profiling Atlas in Cancer (Blood-PAC) committee and leads FDA’s next generation sequencing laboratory collaboration. Dr. Beaver graduated magna cum laude from Princeton University and then earned her medical degree from the University of Pennsylvania School of Medicine. She completed a residency in internal medicine at Johns Hopkins University School of Medicine, followed by a fellowship in medical oncology at The Johns Hopkins Sidney Kimmel Cancer Center.

Ken Pienta

Kenneth J. Pienta, M.D

The Donald S. Coffey Professor Urology, Director, Urology Research Laboratories, Professor Oncology, Pharmacology and Molecular Sciences, Chemical and Biomolecular Engineering

Kenneth J. Pienta is the Donald S. Coffey Professor of Urology and serves as the Director of Research at the Brady Urological Institute of the Johns Hopkins University School of Medicine. He is also a Professor in the Departments of Oncology and Pharmacology and Molecular Science. He serves as a faculty member in the Cellular and Molecular Medicine Program at the Johns Hopkins School of Medicine and is a Professor of Chemical and Biomolecular Engineering in the Whiting School of Engineering at Johns Hopkins University.

Dr. Pienta has a proven track record in organizing and administering a translational research program that successfully incorporates bench research, agent development, and clinical application. Dr. Pienta is a two-time American Cancer Society Clinical Research Professor Award recipient. Between 1995-2013, Dr. Pienta was the Director of the Prostate Specialized Program of Research Excellence (SPORE) at The University of Michigan. Dr. Pienta was the Associate Vice President for Research, Health Sciences, for the University of the Michigan 2012-2013.

Currently, Dr. Pienta is involved in research to define the tumor microenvironment of prostate cancer metastases, as well as developing new therapies for prostate cancer. He is the author of more than 400 peer-reviewed articles, and been the principal investigator on numerous local and national clinical trials. Throughout his career, Dr. Pienta has effectively mentored more than 50 students, residents, and fellows to successful careers in medicine and science.

Peter Silvester

Peter Silvester

Senior Vice President and President, Life Sciences Solutions, Thermo Fisher Scientific

Peter Silvester was appointed Senior Vice President and President, Life Sciences Solutions in 2017. In this role, Peter provides executive oversight of Thermo Fisher Scientific’s Biosciences, Genetic Sciences and Clinical Next-Generation Sequencing businesses as well as Life Sciences Finance, Legal, HR, Licensing and Commercial Supply functions.

Peter’s experience covers many aspects of the life sciences industry including general management, manufacturing, and commercial strategy for technologies which help enable molecular diagnostics and targeted therapeutics for precision medicine. Peter created Thermo Fisher’s first team focused on establishing precision medicine partnerships, and since its inception continues to provide visionary direction for national program efforts across the globe.

Peter has more than 20 years of service with Thermo Fisher across different geographies and operating roles. Prior to his current role, Peter served for four years as President of the Biosciences business, formed following Thermo Fisher’s acquisition of Life Technologies in 2014. He has also served as President of Life Technologies’ Europe, Middle East and Africa (EMEA) region. In this role, Peter led the region through the integration of Invitrogen and Applied Biosystems and focused the team on developing the emerging markets in Russia, South Africa and the Middle East.

Peter was awarded a First Class Honors Degree from the University of Hertfordshire in Applied Biology. Prior to joining Thermo Fisher Scientific, Peter started his career in biotech leading the commercial organization and global distribution network for a DNA synthesis and therapeutics company.

Luis Lasalvia

Luis Lasalvia, MD, MIB

Vice President, Global Medical Officer, Siemens Healthineers

Dr. Luis Lasalvia achievements are driven by his strategic, clinical, and business leadership. Entrepreneur and strategist, Luis has a unique multi disciplinary experience and knowhow, covering several roles in clinical practice, pharmaceutical industry, consultancy/advisory, venturing, and medical devices. Speaker at approx. 500 conferences and events around the world, Luis also authored numerous papers in peer review journals, and submitted a number of patents in the US and Europe.

At Siemens Healthineers, as VP Global Medical Officer, he’s pursuing a modern and effective healthcare. Being a systemic thinker, his sharp focus on clinical and financial value runs across organizations and department levels. He is also leading the entire company wide thought leadership on precision medicine. By partnering with organizations and top thought leaders, Luis is enabling and providing guidance to executives around the globe.

Luis experience includes managing global partnerships, heading companywide Clinical mktg, leading critical multi-million commercial negotiations, running strategy and development of the precision medicine unit, managing strategic innovation, and scouting on business/clinical opportunities.

He’s a Medical Doctor from the Republic University in Montevideo, and holds a Master in International Business from Pompeu Fabra University in Barcelona. He holds executive education at The Wharton School of Business, New York University, and Harvard Business School.

Wendy Rubinstein

Wendy Rubinstein, MD, PhD, FACP, FACMG

Deputy Medical Director of CancerLinQ®, a not-for-profit subsidiary of the American Society of Clinical Oncology (ASCO).

Dr. Wendy Rubinstein is Deputy Medical Director of CancerLinQ®, a not-for-profit subsidiary of the American Society of Clinical Oncology (ASCO). CancerLinQ is ASCO’s physician-led web-based health information technology platform that collects and analyzes data from the electronic health records of participating practices across the United States to help improve the quality of care for patients with cancer.

Dr. Rubinstein directed academic cancer genetics programs for 15 years and has been a member of three NCI-designated Comprehensive Cancer Centers, most recently at the University of Chicago Medical Center. During her tenure as a Senior Scientist at the National Institutes of Health, Dr. Rubinstein launched and directed the NIH Genetic Testing Registry (GTR), now the most comprehensive publicly available information resource about genomic tests in the world. She served as Chief of Medical Genetics and Human Variation at the National Center for Biotechnology Information (NCBI) where she was responsible for flagship information resources including ClinVar, dbSNP, dbGaP, and GTR. Dr. Rubinstein was a representative to the NIH-FDA-CMS Trilateral Genomic Medicine Workgroup and FDA-NIH Interagency Task Force on Laboratory Developed Tests, and received the NIH Director’s Award from Dr. Francis Collins for developing and launching GTR.

An NIH Medical Scientist Training Program scholarship awardee, Dr. Rubinstein earned her MD and PhD at the Mount Sinai School of Medicine in New York City. She holds dual board certification in clinical genetics and clinical molecular genetics (ABMG) and is a Fellow of the American College of Medical Genetics (FACMG) and the American College of Physicians (FACP). A recognized expert in cancer genetics, she has authored and edited publications on gene discovery (SDHD), sequence variant interpretation, genomic population screening, computerized familial risk assessment, pharmacogenomics, genetic modifiers, genomic information resources, clinical guidelines, and health information technology.

Bob Vonderheide

Robert H. Vonderheide, MD, DPhil

Director, Abramson Cancer Center, Perelman School of Medicine and the John H. Glick, MD Abramson Cancer Center’s Director Professor at the University of Pennsylvania

Robert H. Vonderheide, MD, DPhil, is Director, Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania and the John H. Glick, MD Abramson Cancer Center’s Director Professor. Dr. Vonderheide graduated from Oxford University as a Rhodes Scholar, and Harvard Medical School. He completed training in internal medicine and medical oncology at the Massachusetts General Hospital and the Dana Farber Cancer Institute. Dr. Vonderheide is a distinguished scientist and clinician who has deciphered mechanisms of cancer immune surveillance and developed novel cancer therapeutics, particularly in pancreatic cancer. He is well-recognized for driving the development of agonist CD40 antibodies, now in later stage clinical trials as potential immune therapy of cancer. Dr. Vonderheide discovered telomerase as a universal tumor antigen and has led the efforts to develop telomerase vaccination for both therapy and the prevention of cancer in healthy individuals. He has helped lead a team to show that stereotactic radiation therapy in combination with dual checkpoint blockade represents a synergistic path for immune activation in cancer. Dr. Vonderheide merges his clinical investigations with rigorous studies in mouse models or other laboratory systems. Dr. Vonderheide has been continuously funded by the NCI, and his high-impact findings have been published in Nature, Science, Cell and the New England Journal of Medicine.

Erynn Gordon

Erynn Gordon, MS, LCGC

VP of Clinical Operations, Genome Medical

Erynn is a board-certified genetic counselor with expertise in clinical care, research and laboratory genetics. A leader in the genetic counseling community, Erynn has served as President of the American Board of Genetic Counseling and on the National Society of Genetic Counselors Board of Directors. Prior to joining Genome Medical, Erynn was the first genetic counselor at 23andMe, serving as Director of Clinical Affairs. She previously managed a precision medicine study at at the Coriell Institute for Medical Research and held clinical roles at University of Maryland School of Medicine and Children’s National Medical Center.

Ed Abrahams

Edward Abrahams, PhD

President, Personalized Medicine Coalition

Edward Abrahams, Ph.D., is the President of PMC. Representing innovators, scientists, patients, providers and payers, PMC promotes the understanding and adoption of personalized medicine concepts, services and products for the benefit of patients and the health system. It has grown from its original 18 founding members in 2004 to more than 200 today.

Previously, Dr. Abrahams was the Executive Director of the Pennsylvania Biotechnology Association, where he spearheaded the successful effort that led to the Commonwealth of Pennsylvania’s investment of $200 million to commercialize biotechnology in the state. Earlier, he had been Assistant Vice President for Federal Relations at the University of Pennsylvania and held a senior administrative position at Brown University.

Dr. Abrahams worked for seven years for the U.S. Congress, including as a legislative assistant to Senator Lloyd Bentsen, as an economist for the Joint Economic Committee under the chairmanship of Representative Lee Hamilton, and as a AAAS Congressional Fellow for Representative Edward J. Markey.

The author of numerous essays, Dr. Abrahams serves on the editorial board of Personalized Medicine and has also taught history and public policy at Brown University and the University of Pennsylvania.

Hannah Mamuszka

Katie Johansen Taber, PhD.

Director, Clinical Development, Myriad Women’s Health

Katherine (Katie) Johansen Taber, PhD is the Director of Clinical Development at the newly formed Myriad Women’s Health (formerly Counsyl). Her focus is on strategizing, designing, conducting, and publishing studies demonstrating the utility of prenatal and hereditary cancer risk screening in the women’s health setting. She additionally oversees a team working to maintain the clinical excellence of Myriad Women’s Health’s products and services. Before joining Counsyl/Myriad Women’s Health, she spent more than a decade at the American Medical Association, with a primary focus on educating physicians about the clinical implementation of genomics and precision medicine, and on identifying and managing genomics and precision medicine policy issues affecting health care providers. She has held numerous positions on advisory committees and boards of organizations working to improve clinical adoption of genomic technology, including a current appointment on the National Academy of Sciences, Engineering, and Medicine Roundtable on Genomics and Precision Health. Katie earned her PhD in Molecular, Cell, and Developmental Biology at the University of California, Los Angeles, and conducted post-doctoral research at the USDA. She has held teaching appointments at UCLA, California State Polytechnic University, University of Idaho, and Columbia College Chicago.